Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-Week, Randomized, Placebo-Controlled Comparison (GetGoal-L)
Although no clinical trials have examined the impact of GLP-1RAs on Huntingtons disease (HD), more and more evidence in animal models is looking promising (Duarte et al., 2018)
G., Truscott, R
Bachmann C, Colombo JP, Jaggi K (1982) N-acetylglutamate synthetase (NAGS) deficiency: diagnosis, clinical observations and treatment
Neoplasia 12 , 599607 (2010)
If hypoglycemia does occur, the total daily basal and/or prandial insulin dose should be reduced by 1020% if the blood glucose level was 60 Units alternative separate antidiabetes products such as iGlar and lixisenatide should be used